"Mirror Image" Antagonists of Thrombin-induced Platelet Activation Based on Thrombin Receptor Structure

David T. Hung,†‡ Thien-Khai H. Vu,† Virginia I. Wheaton,‡ Israel F. Charo,*,† Nicolaas A. Neiken,‡§ Naomi Esmen,† Charles T. Esmen,†,** and Shaun R. Coughlin***

Department of †Medicine and ‡Surgery, and *Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California 94143; †Cor Therapeutics, Inc., South San Francisco, California 94080; and **Oklahoma Medical Research Foundation and ***Howard Hughes Medical Institute, Oklahoma City, Oklahoma 73104

Abstract

Platelet activation by thrombin plays a critical role in hemostasis and thrombosis. Based on structure–activity studies of a cloned platelet thrombin receptor, we designed two "mirror image" antagonists of thrombin and thrombin receptor function. First, "uncleavable" peptides mimicking the receptor domain postulated to interact with thrombin were found to be potent thrombin inhibitors. Second, proteolytically inactive mutant thrombins designed to bind but not cleave the thrombin receptor were found to be specific antagonists of receptor activation by thrombin. The effectiveness of these designed antagonists in blocking thrombin-induced platelet activation suggests a model for thrombin–receptor interaction and possible strategies for the development of novel antithrombotic agents. (J. Clin. Invest. 1992. 89:444–450.) Key words: active site mutants • inhibitor • peptide • serine proteinases • thrombosis

Introduction

Thrombosis in arterial circulations is a leading cause of morbidity and mortality (1). Platelet activation by thrombin, a multifunctional serine protease evolved at sites of vascular injury, is believed to be a critical event in arterial thrombosis (2). We recently isolated a cDNA clone encoding a functional platelet thrombin receptor (3). The clone encodes a member of the seven transmembrane span family of receptors with a long amino-terminal extracellular extension that contains a thrombin cleavage site (LDPR/SFLL...); with representing the point of cleavage). Carboxyl to the cleavage site lies the sequence DKYEPFWDEE, which resembles the carboxyl tail of the leech anticoagulant hirudin; the carboxyl tail of hirudin is known to bind thrombin's anion-binding exosite (4). Structure–activity studies based on these observations suggest the following working model of thrombin–receptor interaction (3, 5, 6). Thrombin recognizes its receptor by interacting with at least two sites: thrombin's S1–S4 subsites interact with the receptor's cleavage site (the LDPR sequence) and thrombin’s anion-binding exosite interacts with the receptor's hirudin-like DKYEPFWDEE sequence. Thrombin then activates its receptor by cleaving it at the LDPR/SFLL site, unmasking a new receptor amino terminus beginning with the sequence SFLL... This new amino terminus then functions as a tethered peptide ligand, binding to an as yet undefined receptor domain and eliciting receptor activation (3). Based on this proteolytic model of thrombin receptor activation, we have produced two “mirror image” antagonists of thrombin and thrombin receptor function: (a) "uncleavable" receptor-mimicking peptides designed to bind thrombin, preventing thrombin's interaction with its receptor and other substrates, and (b) proteolytically inert mutant thrombins designed to bind but not activate the thrombin receptor, thereby preventing receptor interaction with and subsequent activation by native thrombin. The effectiveness of these antagonists supports the structure–activity relationships described above, further supports the notion that the cloned receptor mediates thrombin-induced platelet activation, and suggests possible strategies for the development of novel antithrombotic agents.

Methods

Materials. Purified human α-thrombin was a generous gift from Dr. John W. Fenton II, Albany Medical College of Union University, Albany, NY. Peptides were made by the University of California, San Francisco Biomolecular Resource Center or were generously provided by Dr. Robert Scarborough, COR Therapeutics, Inc., South San Francisco, CA; peptides were high-pressure liquid chromatography (HPLC)-purified before use.

Preparation of active site mutant thrombins. Oligonucleotide-directed mutagenesis (7) was used to generate the appropriate active site residue substitutions (S205A and D99N/S205A) in a native prothrombin cDNA (8) cloned into a Bluescript SK-plasmid vector system (Stratagene Inc., La Jolla, CA). Successful introduction of the desired mutation(s) was confirmed by DNA sequencing. DNA coding for active site mutant or native prothrombins were subcloned into a pBJ1 expression vector (derived from pcDL SRA296) (9) and co-transfected into dihydrololate reductase minus Chinese hamster ovary (CHO) cells by lipofection (10) with a dihydrololate reductase selection marker in pSV2D (11). Stable transfectants were isolated using nucleoside-deficient medium, and gene amplification was accomplished using 80 nM methotrexate. Recombinant prothrombin production was determined by enzyme-linked immunosorbent assay (ELISA) and Western blots and the highest yielding clones were grown to confluence in a 24,000-cm² surface cell “factory” (Nunc, Inter Med, Naperville, IL) in minimum essential medium (MEM) α-nucleoside-deficient medium with 80 nM methotrexate, 100 U/ml penicillin, 100 μg/ml streptomycin, 25 mM Hepes buffer, 5 μg/ml vitamin K, 0.2 mg/ml proline, and 10% dialyzed bovine calf serum. When the cultures reached full confluence, all medium was removed, all growing surfaces were washed six times with phosphate-buffered saline to remove contaminating bovine prothrombin and thrombin, and cells were grown in MEM α-nucleoside-def-
cient medium containing 100 units/ml penicillin, 100 µg/ml streptomycin, 25 mM Heps buffer, 5 µg/ml vitamin K, 0.2 mg/ml proline, 1 µg/ml insulin and 5 µg/ml transferrin for 36–48 h. Recombinant S205A prothrombin was purified from conditioned media by anion exchange chromatography (12), diluted to ~ 100 µg/ml in 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 0.5% polyethylene glycol (PEG) 6000, and treated for 1 h with prothrombinase complex as previously described (13). pH was then changed to 7.0 with 1 M HCl and the S205A thrombin-containing solution treated with an ~ 1,000-fold molar excess of (p-amidinophenyl)methanesulfonyl fluoride (APMSF) to inhibit factor Xa and any bovine thrombin that might contaminate the preparation. APMSF is a serine-dependent irreversible thrombin antagonist that rapidly inactivates native thrombin at pH 7.0 but has a half-life of only 10^{-5}s at pH 8.0 (14). For this reason, the pH of the APMSF-treated mutant thrombin preparation was then changed to 8.0 for 15 min to eliminate all APMSF. APMSF treatment inactivates native thrombin by modifying the active site serine but does not affect the “serine-less” mutant thrombin (see Fig. 2). The S205A mutant thrombin was then purified by anion exchange chromatography (12), identified by Western blot with anti-human thrombin antisera, a goat antibody directed against reduced, carboxymethylated human α-thrombin, at a 1:2,000 dilution. The concentration and purity of recombinant S205A thrombin preparations were determined by Coomassie and silver-stained SDS-PAGE gels. The mutant thrombin preparations used in these studies appeared homogeneous on silver-stained SDS-PAGE gels.

To control for any residual APMSF remaining in the purified thrombin preparations after pH 8.0 treatment, APMSF-treated mutant thrombin preparations were passed through a Centricron 10 filter (Amicon Corp., Beverly, MA; molecular weight cutoff of 10,000) which retained the recombinant thrombins and all receptor blocking activity. Flowthroughs were tested in amounts greater than those used in platelet experiments and were found to be devoid of any thrombin-inhibiting activity as measured by thrombin-induced hydrolysis of the fluorogenic thrombin substrate 7-phenylalanine-prolyl-arginyl-7-amino-4-trifluoromethyl coumarin (D-Phe-Pro-Arg-AFC; Enzyme Systems Products, Dublin, CA) even when native thrombin concentrations as low as 1 nM were used (data not shown).

Platelet aggregation and ATP secretion studies. Washed platelets were prepared as previously described (15) and unless otherwise noted were suspended in modified Tyrode’s buffer, pH 7.4 with 2 mM magnesium and 1 mM calcium at a concentration of ~ 3 x 10^9 platelets/ml. All platelet studies were performed in a total volume of 500 µl with 20 µl of Chromolium reagent (Chrono-Log Corp., Havertown, PA). Platelet ATP secretion and aggregation were quantitated independently by measuring changes in luminescence and light transmission respectively in a dual-channel lumiaiggrometer (Chrono-Log Corp.) (16). Stirred platelets were used to ensure rapid and uniform distribution of agonist and initial rates of secretion were determined as defined in the appropriate figure legends.

Voltage-clamped oocyte studies. Xenopus oocytes were harvested from female Xenopus laevis and procured in affected techniques (17, 18). Individual oocytes were microinjected with cloned functional platelet thrombin receptor cRNA and cultured for 48 h at 18°C in modified Barth’s solution (3). Oocytes were voltage clamped at −40 to −60 mV and agonist-induced inward Cl− currents were measured (3, 19).

Results and Discussion

To determine whether “noncleavable” peptides representing the receptor’s cleavage site and thrombin binding domains could bind thrombin and act as thrombin inhibitors, the peptide LDPRFLLRNPDKYEPFWDEEKNES (peptide 1) was first synthesized. This peptide represents the native receptor sequence encompassing the cleavage recognition sequence LDLR/S and the putative anion-binding exosite binding sequence DKYEPFWDEE (3, 5, 6); the serine in the receptor’s P1 position has been replaced by a proline (residue 5 in the peptide) to slow hydrolysis of the peptide by thrombin. As shown in Fig. 1 (left), this peptide was a potent inhibitor of thrombin-induced platelet secretion even when high thrombin concentrations were employed; the IC_{50} to block 10 nM thrombin was ~ 400 nM peptide. These data strongly suggest that receptor domains represented within peptide 1 bind thrombin and play an important role in thrombin–receptor interaction.

To determine whether merely interacting with thrombin’s small substrate recognition site (i.e., the S1–S4 subsites) could account for the potent antagonist activity of peptide 1, the shorter peptide LDPRFLL (peptide 2) was synthesized. This peptide lacks the anion-binding exosite binding domain sequence (DKYEPFWDEE) found in peptide 1, and was 500-fold less potent (IC_{50} for 10 nM thrombin, 200 µM) than peptide 1 in blocking thrombin-induced platelet activation (Fig. 1, left vs. middle). This result is consistent with the “two site” model of thrombin receptor interaction presented in the introduction, in which recognition of both the receptor’s LDLR

---

1. Abbreviations used in this paper: AFC, amino-4-trifluoromethyl coumarin; APMSF, (p-amidinophenyl)methanesulfonyl fluoride; DIP, diisopropyl fluorophosphate; MES, 2-(N-morphino) ethane sulfonic acid; PPACK, D-Phe-Pro-Arg chloromethyl ketone.
cleavage recognition sequence and its hirudin-like DYEPF-WEDEE sequence are critical for effective interaction with thrombin.

Because structure activity studies with protein C have suggested that the LDPR sequence is not an optimal recognition site for cleavage by thrombin (20) and because the sequence D-Phe-Pro-Arg is known to bind to thrombin's S1–S3 subsites effectively (21), we produced a receptor peptide (peptide 3) corresponding to peptide 1 but with the Leu-Asp-Pro-Arg sequence replaced by the sequence D-Phe-Pro-Arg. As shown in Fig. 1 (right), peptide 3 was fourfold more potent than the native sequence peptide 1 in blocking thrombin-induced responses (IC50 for 10 nM thrombin, 100 nM). This receptor-based peptide is functionally similar to another thrombin-inhibiting peptide, hirulog, in which a D-Phe-Pro-Arg sequence was coupled to the carboxyl tail of hirudin (22). The increase in the inhibitory potency of the receptor-based peptide seen upon replacing the LDPR sequence with D-Phe-Pro-Arg strongly suggests that the amino acids in these positions interact with thrombin's S1–S3 subsites, in agreement with the model presented above.

The specificity of the thrombin receptor-based peptides was shown by their inability to inhibit platelet activation by other agonists. When thrombin was used at its EC50 for platelet activation (1 nM), the IC50's for peptides 1, 2, and 3 were ~ 200 nM, 30 μM, and 50 nM, respectively. These concentrations of peptide had no effect on platelet ATP secretion or aggregation induced by EC50 concentrations of arachidonate, A23187, or thrombin receptor agonist peptide SFLRNPNDKYEPF. The latter mimics the receptor amino terminus unmasked upon receptor cleavage by thrombin, thereby bypassing the cleavage step to directly activate the receptor (3). These data demonstrate that "noncleavable" peptides representing the receptor domains postulated to interact with thrombin do indeed function as specific thrombin inhibitors with a rank order of potency predicted by the structure–activity relationships outlined above.

If a noncleavable receptor-based peptide could function as a thrombin inhibitor by binding thrombin and preventing its interaction with the thrombin receptor, a proteolytically inert thrombin might be predicted to function as a receptor antagonist by binding to the receptor and blocking its interaction with native thrombin. Based on the two-site model of thrombin-receptor interaction presented above, we particularly wanted a proteolytically inactive thrombin in which both the active site/S1–S4 subsite region and the anion-binding exosite region had preserved binding functions. To produce proteolytically inert thrombins with preserved binding functions, recombinant thrombins with amino acid substitutions at the serine protease catalytic triad were created. In thrombin, the serine, histidine, and aspartate residues that participate in catalysis are located at β-chain positions 205, 57, and 99, respectively. Craik and colleagues have demonstrated that amino acid substitutions at the analogous active site residues in trypsin abolish trypsin's protease activity without significantly altering its substrate binding properties or crystal structure (23, 24). Based on these observations, we produced recombinant thrombin mutants containing the single amino acid substitution of alanine for serine at β-chain position 205 ("S205A") and the double substitution containing an additional asparagine for aspartate substitution at β-chain position 99 ("D99N/S205A").

Recombinant native thrombin as well as mutant thrombins S205A and D99N/S205A were produced from the corresponding prothrombins expressed in CHO fibroblasts (8) (see Methods). The specific activity of the recombinant native thrombin could not be distinguished from that of homogeneous, nonrecombinant thrombin by fibrinogen clotting or amidolytic activity using the fluorescent thrombin substrate D-Phe-Pro-Arg-AFC. By contrast, the S205A and D99N/S205A mutant thrombins exhibited no detectable amidolytic or fibrinogen clotting activity, even when mutant thrombin concentrations as high as 400 nM were employed (data not shown). It should be noted that the S205A mutant thrombin differs from native thrombin by only a single oxygen atom.

In contrast to the loss of protease activity caused by the amino acid substitutions at the protease active site, the binding functions of both the active/small substrate binding region and the anion-binding exosite were preserved in the mutant thrombins. The function of the active site/small substrate binding pocket region was examined by assessing the ability of the mutant thrombins to bind benzamidine and D-Phe-Pro-Arg-AFC. Both recombinant native and mutant thrombins retained the ability to bind benzamidine (Fig. 2), a reversible inhibitor of serine proteases which specifically occupies the small substrate binding pocket/S1 subsite (25). The recombinant mutant thrombins were also able to bind and sequester the fluorogenic thrombin substrate D-Phe-Pro-Arg-AFC, thereby blocking its hydrolysis by native thrombin (data not shown). D-Phe-ProArg-AFC occupies thrombin's S1–S3 subsites (21, 26). These observations strongly suggest that the active site/S1–S3 subsite region of S205A thrombin retains binding function. This is in contrast to thrombins rendered proteolytically inactive by chemical modifications of the active site, such as D-Phe-ProArg-chloromethyl ketone (PPACK)- or APMSF-thrombin. The active site/small substrate binding region of these thrombins is occupied and cannot participate in substrate binding (14, 21), hence their inability to bind benzamidine (Fig. 2). It is likely that the other binding surfaces on these thrombins, including the anion-binding exosite, remain functional. Nonetheless, the loss of one of two binding surfaces thought to be important in thrombin-receptor interaction in the chemically modified thrombins suggested that the recombinant mutant thrombins might be better thrombin receptor-binding reagents.

Active site-independent binding functions of the S205A mutant thrombin were assessed by examining its ability to bind thrombomodulin. As shown in Fig. 3, S205A thrombin inhibited thrombomodulin-dependent activation of protein C by wild-type thrombin with an IC50 of ~ 0.3 nM, indistinguishable from that of DIP-thrombin. The potency of the S205A mutant thrombin in competing with native thrombin in this assay suggests that sites required for thrombomodulin binding, including thrombin's anion-binding exosite, remain functional in the mutant thrombin.

To determine whether the active site mutant thrombin was capable of interacting with the cloned thrombin receptor, we examined the ability of S205A mutant thrombin to block thrombin-induced responses in Xenopus oocytes expressing thrombin receptor cRNA (3). As shown in Fig. 3, in oocytes expressing thrombin receptor cRNA, native thrombin elicited a calcium-dependent inward chloride current reflecting an increase in cytosolic calcium, a normal thrombin-induced sec-
ond messenger event (3). By contrast, the recombinant S205A mutant thrombin was incapable of inducing an inward current in oocytes expressing the cloned platelet thrombin receptor, even when employed at concentrations as high as 400 nM (Fig. 4). Strikingly, the active site mutant thrombins were potent antagonists of thrombin-induced activation of thrombin receptor-expressing oocytes but did not block oocyte activation by submaximal (EC_{33}) concentrations of the thrombin receptor agonist peptide SFLLRNPNDKYEFP (Fig. 4); this peptide mimics the new amino terminus unmasked by thrombin-mediated receptor cleavage and can therefore activate the receptor directly, bypassing the requirement for receptor cleavage (3). These results suggest that the blockade of thrombin receptor activation by S205A thrombin is due to inhibition of receptor proteolysis by native thrombin and not to a more general perturbation of receptor function.

The active site mutant thrombins not only blocked thrombin responses in the oocyte system; they were also effective antagonists of thrombin-induced platelet activation. Preincubation of platelets with the S205A mutant thrombin markedly attenuated both the initial rate (Fig. 5) and extent of thrombin-induced platelet secretion (Fig. 6). Preincubation with mutant thrombin caused marked delays in thrombin-induced platelet aggregation as well. The inhibitory activity of these mutant thrombin preparations could be removed by adsorption to benzamidine-Sepharose but not to unsubstituted Sepharose (data not shown), strongly suggesting that the inhibitory activity of the mutant thrombin preparations was due to the recombinant protein itself.

Inhibition of platelet activation by the S205A mutant thrombin was specific for thrombin-induced responses, in that the mutant protein had no effect on platelet secretion induced by submaximal stimulating concentrations of thrombin receptor agonist peptide SFLLRNPNDKYEFP or A23187 (Fig. 7). These data strongly suggest that the S205A mutant thrombin blocks thrombin responses by specifically binding to the platelet thrombin receptor, thereby preventing receptor proteolysis and activation by the wild-type enzyme. The observation that high concentrations of active site mutant thrombin (400 nM) are required to block thrombin receptor activation by EC_{30}. 

**Figure 2.** Determination of active site/small substrate binding region function: ability to bind benzamidine beads. Approximately 350 ng nonrecombinant native thrombin (lanes 1–3), recombinant native thrombin (lanes 4–6), D99N/S205A mutant thrombin (lanes 7–9), D-Phe-Pro-Arg-chloromethyl ketone (PPACK)-treated thrombin (lanes 10–12) (26), and APMSF-thrombin (lanes 13–15) (14) in 82 μl of 170 mM NaCl, 10 mM 2-(N-morpholino) ethane sulfonic acid (MES), pH 7.4, 0.5% PEG 6000 were incubated with 36 μl of either 50% (vol/vol) Sepharose 2B or p-aminobenzamidine-linked Sepharose (Pierce Chemical Co., Rockford, IL) for 3 h at room temperature. The Sepharose beads were pelleted by centrifugation and the supernatants analyzed by 9% SDS-PAGE gel electrophoresis under reducing conditions, followed by immunoblot with thrombin antiserum. These results are representative of results obtained in five replicate experiments. S205A mutant thrombin behaved identically to D99N/S205A mutant thrombin with respect to benzamidine binding (data not shown).

**Figure 3.** Inhibition of thrombin-thrombomodulin activation of protein C by DIP-thrombin and S205A thrombin. Bovine protein C (1 μM) was activated in a solution (0.1 M NaCl, 0.02 M Tris-HCl, pH 7.5, 5 mM CaCl₂, 0.1% gelatin) containing 0.1 nM human thrombin, 0.2 nM rabbit thrombomodulin, and the indicated concentrations of DIP-thrombin (○) or the S205A thrombin mutant (●). After 30 min at 37°C, antithrombin III was added to inhibit the thrombin and the activated protein C generated was measured by its activity vs. the chromogenic substrate S2238 (KabiVitrum, Stockholm, Sweden). The rates of activation are compared to that observed in the absence of inhibitor.

**Figure 4.** Determination of active site/small substrate binding region function: ability to bind benzamidine beads. Approximately 350 ng nonrecombinant native thrombin (lanes 1–3), recombinant native thrombin (lanes 4–6), D99N/S205A mutant thrombin (lanes 7–9), D-Phe-Pro-Arg-chloromethyl ketone (PPACK)-treated thrombin (lanes 10–12) (26), and APMSF-thrombin (lanes 13–15) (14) in 82 μl of 170 mM NaCl, 10 mM 2-(N-morpholino) ethane sulfonic acid (MES), pH 7.4, 0.5% PEG 6000 were incubated with 36 μl of either 50% (vol/vol) Sepharose 2B or p-aminobenzamidine-linked Sepharose (Pierce Chemical Co., Rockford, IL) for 3 h at room temperature. The Sepharose beads were pelleted by centrifugation and the supernatants analyzed by 9% SDS-PAGE gel electrophoresis under reducing conditions, followed by immunoblot with thrombin antiserum. These results are representative of results obtained in five replicate experiments. S205A mutant thrombin behaved identically to D99N/S205A mutant thrombin with respect to benzamidine binding (data not shown).
concentrations of native thrombin in both platelets and oocytes expressing a functional thrombin receptor is consistent with kinetic predictions for blockade of an irreversible event (i.e., thrombin receptor proteolysis by native thrombin) using a competitive antagonist (i.e., the active site mutant thrombins).

Most efforts to block thrombin-induced platelet activation using chemically modified DIP, TLCK thrombins have been unsuccessful (27, 28). This is likely due in part to residual agonist activity from incomplete thrombin inactivation by chemical active site blockers (29). In addition, the two-site model of thrombin (data not shown). Right: 400 nM S205A thrombin right-shifts the dose response of platelets to native thrombin by ~1 log; 18 μl of mutant thrombin (dotted lines) in 600 mM NaCl, 10 mM MES, pH 6.0, 0.5% PEG 6000 buffer to give a final mutant thrombin concentration of 400 nM or an equal volume of buffer alone (solid lines) were incubated with 500 μl of platelets for 15 min at 37°C. Platelets were then stimulated with the indicated final concentrations of α-thrombin; platelet ATP secretion and aggregation were followed for 30 s after thrombin addition. The data shown reflect the maximum initial rate of platelet ATP secretion, specifically, the maximum rate of platelet ATP secretion occurring within 30 s of agonist addition and before any aggregation was detected. Thus the platelet ATP secretion rates reported represent only agonist-induced and not aggregation-induced responses (16). Curves from three replicate experiments are shown. One arbitrary unit corresponds to 33 pmol of ATP released per second based on calibration with ATP standards.
Figure 6. S205A thrombin inhibits the extent of native thrombin-induced platelet secretion. Platelets were preincubated with the indicated concentrations of mutant thrombin as described in the legend to Fig. 4, then stimulated with native thrombin (1 nM final concentration). To prevent aggregation-induced secretion, platelets in these experiments were suspended to a final concentration of 2 x 10⁷ platelets/ml and were not stirred after the addition of native thrombin. Under these conditions, platelets did not aggregate but did secrete ATP in response to thrombin. Platelet secretion rate is expressed in arbitrary units as defined in the legend to Fig. 4. These figures are tracings of platelet secretion curves, and are representative of the results obtained in three replicate experiments. The decrease in luminescence seen in the control curve (0) is characteristic of the assay and may represent end-product inhibition of luciferase (16).

thrombin–receptor interaction proposed above predicts that loss of the active site/S1–S3 substrate binding determinant upon chemical modification leaves only the thrombin anion-binding exosite available for interaction with the thrombin receptor, thereby decreasing receptor binding. The observation that DIP- and TLCK-thrombins bind to cells identically to native thrombin suggests that most thrombin-binding sites detected by classical binding studies are unrelated to the functional thrombin receptor (see below). In contrast to DIP- and TLCK-thrombins, PPACK-thrombin has been reported to block thrombin-induced platelet activation when used at high concentration (29). This difference may be due to the higher efficiency of thrombin inactivation by PPACK (29) and suggests that occupancy of thrombin’s S1–S3 subsites does not abolish all ability to interact with the thrombin receptor. Indeed, a peptide representing only the receptor’s anion-binding exosite binding domain has been shown to bind thrombin with a Kᵦ of ~ 32 μM (6). To date, we have not been able to directly study receptor-dependent binding of the recombinant mutant thrombins to either platelets or thrombin receptor-expressing oocytes or mammalian cell lines because of the preponderance of high-affinity thrombin binding sites unrelated to the cloned receptor (glycoprotein Ib in platelets, protease nexins, or other proteins in oocytes and mammalian cells). However, the observation that peptides based on receptor sequence can interact with thrombin and block its function (Fig. 1) as well as recent studies demonstrating the binding of receptor peptides to thrombin (6) provides independent evidence for direct interactions between thrombin and the thrombin receptor’s amino terminal extension.

In summary, we have designed two groups of thrombin receptor antagonists based on structure–activity studies of a cloned functional platelet thrombin receptor: (a) “uncleavable” receptor-mimicking peptides designed to bind thrombin, preventing thrombin’s interaction with its receptor and other substrates, and (b) proteolytically inert mutant thrombins designed to bind but not activate the thrombin receptor, thereby preventing receptor interaction with native thrombin. The effectiveness of the “uncleavable” receptor-based thrombin-inhibiting peptides is consistent with the proteolytic model of thrombin receptor activation, and the differing potencies of these peptides support the model that thrombin directly interacts with both the receptor’s cleavage recognition site LDPR/S and its anion-binding exosite binding sequence DKYEPFWEDEE. The potency of these receptor-based peptides in blocking thrombin-induced platelet activation also supports the hypothesis that the cloned thrombin receptor mediates platelet activation. The proteolytic mechanism of receptor activation is further supported by the fact that selective elimination of a single oxygen atom from thrombin’s active site abolished thrombin’s protease and platelet-stimulating activities without impairing any thrombin binding functions measured. Specifically, the S205A mutant thrombin retained the ability to bind but not activate the platelet thrombin receptor as evidenced by its ability to block activation of a functional platelet thrombin receptor expressed in oocytes in addition to blocking thrombin-induced platelet activation. The efficacy of these molecular reagents in blocking thrombin-induced platelet activation and the model of thrombin–receptor interaction supported by these studies provide a basis for novel structure–activity studies of thrombin–receptor interaction using further mutations of the S205A thrombin. Lastly, these studies also suggest possible strategies for the development of new antithrombotic agents; the receptor-mimicking peptides are most promising in this regard.

Acknowledgments

We thank Dr. John Fenton II (Wadsworth Center/Albany Medical College) for his generous gift of α-thrombin, Dr. Mark Davis (Stanford
and Drs. Bruce and Barbara Furie (Tufts-New England Medical Center) for their generous gift of native human prothrombin cDNA used in these studies. We also thank Dr. Charles S. Craik for valuable discussions and Drs. Henry R. Bourne, Marc A. Shuman, Lewis T. Williams, and David J. Julius for their critical review of the manuscript for this article.

This work was supported in part by the Physician-Scientist Award HL0248-01 (Dr. Hung), the Tobacco-Related Disease Research Program of the University of California, HL-44907, and HL-43821 (Dr. Coughlin), and Howard Hughes Medical Institute (Dr. Esmon). This work was done during the tenure of an award from the American Heart Association and SmithKline Beecham to Dr. Coughlin.

References